Thromboembolic event, Cancer
Conditions
Brief summary
Occult cancer “missed” by cancer screening defined as proven cancer diagnosed (either biopsy proven cancer or cancer diagnosis approved by adjudication committee in the absence of biopsy proven cancer) from the time of cancer screening completion to the end of the 1-year follow-up period, and not detected at the time of screening.
Detailed description
1) New cancer diagnosis after completion of the initial allocated screening strategy., 2) Early-stage (T1-2N0M0 as per the World Health Organization TNM classification system) and advanced-stage tumors at initial screening and during follow-up., 3) Cancer-related mortality during a 5-year follow-up period., 4) Diagnosis of cancer and costs from the viewpoint of the healthcare system over a one-year period in order to estimate the additional cost per additional cancer detected and the incremental cost utility ratio, 5) Additional tests following each strategy and during follow-up., 6) The data of this study will be used to develop a decision aid to assist future patients in the decision of cancer screening
Interventions
Sponsors
Centre Hospitalier Regional Et Universitaire De Brest
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occult cancer “missed” by cancer screening defined as proven cancer diagnosed (either biopsy proven cancer or cancer diagnosis approved by adjudication committee in the absence of biopsy proven cancer) from the time of cancer screening completion to the end of the 1-year follow-up period, and not detected at the time of screening. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) New cancer diagnosis after completion of the initial allocated screening strategy., 2) Early-stage (T1-2N0M0 as per the World Health Organization TNM classification system) and advanced-stage tumors at initial screening and during follow-up., 3) Cancer-related mortality during a 5-year follow-up period., 4) Diagnosis of cancer and costs from the viewpoint of the healthcare system over a one-year period in order to estimate the additional cost per additional cancer detected and the incremental cost utility ratio, 5) Additional tests following each strategy and during follow-up., 6) The data of this study will be used to develop a decision aid to assist future patients in the decision of cancer screening | — |
Countries
France
Outcome results
None listed